- Hayato Mizuta, .et al. Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer, Nat Commun, 2021, Feb 24;12(1):1261 PMID: 33627640
- Keisuke Yanagida, .et al. Sphingosine 1-Phosphate Receptor Signaling Establishes AP-1 Gradients to Allow for Retinal Endothelial Cell Specialization, Dev Cell, 2020, 52 (6), 779-793 PMID: 32059774
- Hamzehlou S, .et al. Anti-tumor activity of neratinib, a pan-HER inhibitor, in gastric adenocarcinoma cells, Eur J Pharmacol, 2019, Nov 15;863:172705 PMID: 31574259
- Kanemaru Y, .et al. Dramatic response of BRAF V600E-mutant epithelioid glioblastoma to combination therapy with BRAF and MEK inhibitor: establishment and xenograft of a cell line to predict clinical efficacy, Acta Neuropathol Commun, 2019, Jul 25;7(1):119 PMID: 31345255
- Chul Min Park, .et al. Mechanisms for DNA-damaging agent-induced inactivation of ErbB2 and ErbB3 via the ERK and p38 signaling pathways, Oncol Lett, 2018, Feb; 15(2): 1758-1762 PMID: 29434871
- Sumi T, .et al. Trametinib downregulates survivin expression in RB1-positive KRAS-mutant lung adenocarcinoma cells, Biochem Biophys Res Commun, 2018, Jun 18;501(1):253-258 PMID: 29727601
- Toshiyuki Sumi, .et al. Survivin knockdown induces senescence in TTF-1-expressing, KRAS-mutant lung adenocarcinomas, Int J Oncol, 2018, Jul; 53(1): 33-46 PMID: 29658609
- Fujita KI, .et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
- Yuki Kawasaki, .et al. Feedback control of ErbB2 via ERK-mediated phosphorylation of a conserved threonine in the juxtamembrane domain, Sci Rep, 2016, 6: 31502 PMID: 27531070
Biological Activity
GSK1120212 (JTP-74057) strongly prevented the activities of MEK1 and MEK2 kinases rather than activities of other 98 kinases.
Targets
MEK1 (Cell-free assay) | MEK2 (Cell-free assay) | |||
0.92 nM | 1.8 nM |
In vitro (25°C) | DMSO | Warmed: 19 mg/mL (30.87 mM) | |
Water | Insoluble | ||
Ethanol | Insoluble | ||
In vivo | 4% DMSO+corn oil | 2 mg/mL | |
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.1 mM | 16.25 mL | 81.25 mL | 162.5 mL |
0.5 mM | 3.25 mL | 16.25 mL | 32.5 mL |
1 mM | 1.62 mL | 8.12 mL | 16.25 mL |
5 mM | 0.32 mL | 1.62 mL | 3.25 mL |
*The above data is based on the productmolecular weight 615.4 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
Catalog Num | A11029 |
---|---|
Actions | Inhibitor |
CAS No. | 871700-17-3 |
Formula | C26H23FIN5O4 |
M. Wt | 615.4 |
Purity | >98% |
Synonyms | GSK-1120212, GSK212, Trametinib |
SMILES | CC1=C2C(=C(N(C1=O)C)NC3=C(C=C(C=C3)I)F)C(=O)N(C(=O)N2C4=CC(=CC=C4)NC(=O)C)C5CC5 |
Storage | Store lyophilized at -20ºC, keep desiccated. |
Datasheet
Product Tags
Product Questions
Product Questions
No Questions
You may also be interested in the following product(s)
PD0325901
PD0325901 is MEK inhibitor and non-competitive with ATP, Kiapp of 1 nM against activated MEK1 and MEK2.
RO4927350
RO4927350 a potent and highly selective non-ATP-competitive MEK1/2 inhibitor.
GDC-0623
GDC-0623 is a potent and ATP-uncompetitive MEK1 inhibitor with Ki of 0.13 nM. Phase 1.
TAK-733
TAK-733 is an orally bioavailable small-molecule inhibitor of MEK1 and MEK2 (MEK1/2) with potential antineoplastic activity.
RO4987655
RO4987655 is an orally active small molecule, targeting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), with potential antineopl…
GDC-0973 (Cobimetinib)
Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively f…
BI-847325
BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xen…
AS703026 (Pimasertib)
AS703026 is a novel, selective, orally bioavailable MEK1/2 inhibitor that inhibits growth and survival of MM cells and cytokine-induced oste…
Keywords:buy GSK1120212 (JTP-74057, Trametinib) | GSK1120212 (JTP-74057, Trametinib) Supplier | purchase | cost | manufacturer | order | distributor | buy 871700-17-3| 871700-17-3 Supplier | purchase 871700-17-3 | 871700-17-3 cost | 871700-17-3 manufacturer | order 871700-17-3 | 871700-17-3 distributor